ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Pulmonary Hypertension (PPH) Treatment Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-33Y16129
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Primary Pulmonary Hypertension PPH Treatment Market Research Report 2023
BUY CHAPTERS

Global Primary Pulmonary Hypertension (PPH) Treatment Market Research Report 2025

Code: QYRE-Auto-33Y16129
Report
June 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
GlaxoSmithKline PLC
Bayer HealthCare
United Therapeutics Corp.
Novartis lnternational AG

Primary Pulmonary Hypertension (PPH) Treatment Market

The global market for Primary Pulmonary Hypertension (PPH) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Primary Pulmonary Hypertension (PPH) Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Primary Pulmonary Hypertension (PPH) Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Primary Pulmonary Hypertension (PPH) Treatment include Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis lnternational AG, Bayer HealthCare, United Therapeutics Corp., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Primary Pulmonary Hypertension (PPH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Pulmonary Hypertension (PPH) Treatment.
The Primary Pulmonary Hypertension (PPH) Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Primary Pulmonary Hypertension (PPH) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Pulmonary Hypertension (PPH) Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Primary Pulmonary Hypertension (PPH) Treatment Market Report

Report Metric Details
Report Name Primary Pulmonary Hypertension (PPH) Treatment Market
Segment by Type
  • Prostacyclin & Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 (PDE-5)Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
Segment by Application
  • Early-stage Drug Candidates (Phase l & Phase ll)
  • Late-stage Drug Candidates (Phase ll & Registration Phase)
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis lnternational AG, Bayer HealthCare, United Therapeutics Corp.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Primary Pulmonary Hypertension (PPH) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Primary Pulmonary Hypertension (PPH) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Primary Pulmonary Hypertension (PPH) Treatment Market report?

Ans: The main players in the Primary Pulmonary Hypertension (PPH) Treatment Market are Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis lnternational AG, Bayer HealthCare, United Therapeutics Corp.

What are the Application segmentation covered in the Primary Pulmonary Hypertension (PPH) Treatment Market report?

Ans: The Applications covered in the Primary Pulmonary Hypertension (PPH) Treatment Market report are Early-stage Drug Candidates (Phase l & Phase ll), Late-stage Drug Candidates (Phase ll & Registration Phase)

What are the Type segmentation covered in the Primary Pulmonary Hypertension (PPH) Treatment Market report?

Ans: The Types covered in the Primary Pulmonary Hypertension (PPH) Treatment Market report are Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5)Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators

1 Primary Pulmonary Hypertension (PPH) Treatment Market Overview
1.1 Product Definition
1.2 Primary Pulmonary Hypertension (PPH) Treatment by Type
1.2.1 Global Primary Pulmonary Hypertension (PPH) Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 Prostacyclin & Prostacyclin Analogs
1.2.3 Endothelin Receptor Antagonists (ERAs)
1.2.4 Phosphodiesterase-5 (PDE-5)Inhibitors
1.2.5 Soluble Guanylate Cyclase (sGC) Stimulators
1.3 Primary Pulmonary Hypertension (PPH) Treatment by Application
1.3.1 Global Primary Pulmonary Hypertension (PPH) Treatment Market Value by Application (2024 VS 2031)
1.3.2 Early-stage Drug Candidates (Phase l & Phase ll)
1.3.3 Late-stage Drug Candidates (Phase ll & Registration Phase)
1.4 Global Primary Pulmonary Hypertension (PPH) Treatment Market Size Estimates and Forecasts
1.4.1 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue 2020-2031
1.4.2 Global Primary Pulmonary Hypertension (PPH) Treatment Sales 2020-2031
1.4.3 Global Primary Pulmonary Hypertension (PPH) Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Primary Pulmonary Hypertension (PPH) Treatment Market Competition by Manufacturers
2.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Primary Pulmonary Hypertension (PPH) Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Primary Pulmonary Hypertension (PPH) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Product Type & Application
2.7 Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Date of Enter into This Industry
2.8 Global Primary Pulmonary Hypertension (PPH) Treatment Market Competitive Situation and Trends
2.8.1 Global Primary Pulmonary Hypertension (PPH) Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Primary Pulmonary Hypertension (PPH) Treatment Players Market Share by Revenue
2.8.3 Global Primary Pulmonary Hypertension (PPH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Primary Pulmonary Hypertension (PPH) Treatment Market Scenario by Region
3.1 Global Primary Pulmonary Hypertension (PPH) Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Region: 2020-2031
3.2.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Region: 2020-2025
3.2.2 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Region: 2026-2031
3.3 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region: 2020-2031
3.3.1 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region: 2020-2025
3.3.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region: 2026-2031
3.4 North America Primary Pulmonary Hypertension (PPH) Treatment Market Facts & Figures by Country
3.4.1 North America Primary Pulmonary Hypertension (PPH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2031)
3.4.3 North America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary Pulmonary Hypertension (PPH) Treatment Market Facts & Figures by Country
3.5.1 Europe Primary Pulmonary Hypertension (PPH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2031)
3.5.3 Europe Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Primary Pulmonary Hypertension (PPH) Treatment Market Facts & Figures by Country
3.7.1 Latin America Primary Pulmonary Hypertension (PPH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2031)
3.7.3 Latin America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Type (2020-2031)
4.1.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Type (2020-2025)
4.1.2 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Type (2026-2031)
4.1.3 Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Type (2020-2031)
4.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Type (2020-2031)
4.2.1 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Type (2020-2025)
4.2.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Type (2026-2031)
4.2.3 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Primary Pulmonary Hypertension (PPH) Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Application (2020-2031)
5.1.1 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Application (2020-2025)
5.1.2 Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Application (2026-2031)
5.1.3 Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Application (2020-2031)
5.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Application (2020-2031)
5.2.1 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Application (2020-2025)
5.2.2 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Application (2026-2031)
5.2.3 Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Primary Pulmonary Hypertension (PPH) Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Gilead Sciences Inc.
6.1.1 Gilead Sciences Inc. Company Information
6.1.2 Gilead Sciences Inc. Description and Business Overview
6.1.3 Gilead Sciences Inc. Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Gilead Sciences Inc. Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.1.5 Gilead Sciences Inc. Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Company Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Inc. Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Company Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Plc Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 Novartis lnternational AG
6.4.1 Novartis lnternational AG Company Information
6.4.2 Novartis lnternational AG Description and Business Overview
6.4.3 Novartis lnternational AG Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis lnternational AG Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.4.5 Novartis lnternational AG Recent Developments/Updates
6.5 Bayer HealthCare
6.5.1 Bayer HealthCare Company Information
6.5.2 Bayer HealthCare Description and Business Overview
6.5.3 Bayer HealthCare Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bayer HealthCare Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.5.5 Bayer HealthCare Recent Developments/Updates
6.6 United Therapeutics Corp.
6.6.1 United Therapeutics Corp. Company Information
6.6.2 United Therapeutics Corp. Description and Business Overview
6.6.3 United Therapeutics Corp. Primary Pulmonary Hypertension (PPH) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 United Therapeutics Corp. Primary Pulmonary Hypertension (PPH) Treatment Product Portfolio
6.6.5 United Therapeutics Corp. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Pulmonary Hypertension (PPH) Treatment Industry Chain Analysis
7.2 Primary Pulmonary Hypertension (PPH) Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Pulmonary Hypertension (PPH) Treatment Production Mode & Process Analysis
7.4 Primary Pulmonary Hypertension (PPH) Treatment Sales and Marketing
7.4.1 Primary Pulmonary Hypertension (PPH) Treatment Sales Channels
7.4.2 Primary Pulmonary Hypertension (PPH) Treatment Distributors
7.5 Primary Pulmonary Hypertension (PPH) Treatment Customer Analysis
8 Primary Pulmonary Hypertension (PPH) Treatment Market Dynamics
8.1 Primary Pulmonary Hypertension (PPH) Treatment Industry Trends
8.2 Primary Pulmonary Hypertension (PPH) Treatment Market Drivers
8.3 Primary Pulmonary Hypertension (PPH) Treatment Market Challenges
8.4 Primary Pulmonary Hypertension (PPH) Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
GlaxoSmithKline PLC
Bayer HealthCare
United Therapeutics Corp.
Novartis lnternational AG
List of Tables
 Table 1. Global Primary Pulmonary Hypertension (PPH) Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Primary Pulmonary Hypertension (PPH) Treatment Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Primary Pulmonary Hypertension (PPH) Treatment Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Primary Pulmonary Hypertension (PPH) Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Primary Pulmonary Hypertension (PPH) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Product Type & Application
 Table 12. Global Key Manufacturers of Primary Pulmonary Hypertension (PPH) Treatment, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Primary Pulmonary Hypertension (PPH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Pulmonary Hypertension (PPH) Treatment as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Primary Pulmonary Hypertension (PPH) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Region (2020-2025) & (K Units)
 Table 18. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Region (2020-2025)
 Table 19. Global Primary Pulmonary Hypertension (PPH) Treatment Sales by Region (2026-2031) & (K Units)
 Table 20. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Region (2026-2031)
 Table 21. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Region (2020-2025)
 Table 23. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Region (2026-2031)
 Table 25. North America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 27. North America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 28. North America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units) by Type (2020-2025)
 Table 51. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units) by Type (2026-2031)
 Table 52. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Type (2020-2025)
 Table 53. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Type (2026-2031)
 Table 54. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Type (2020-2025)
 Table 57. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Type (2026-2031)
 Table 58. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units) by Application (2020-2025)
 Table 61. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units) by Application (2026-2031)
 Table 62. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Application (2020-2025)
 Table 63. Global Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Application (2026-2031)
 Table 64. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Application (2020-2025)
 Table 67. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Application (2026-2031)
 Table 68. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Application (2026-2031)
 Table 70. Gilead Sciences Inc. Company Information
 Table 71. Gilead Sciences Inc. Description and Business Overview
 Table 72. Gilead Sciences Inc. Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Gilead Sciences Inc. Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 74. Gilead Sciences Inc. Recent Developments/Updates
 Table 75. Pfizer Inc. Company Information
 Table 76. Pfizer Inc. Description and Business Overview
 Table 77. Pfizer Inc. Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Pfizer Inc. Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 79. Pfizer Inc. Recent Developments/Updates
 Table 80. GlaxoSmithKline Plc Company Information
 Table 81. GlaxoSmithKline Plc Description and Business Overview
 Table 82. GlaxoSmithKline Plc Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Plc Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 84. GlaxoSmithKline Plc Recent Developments/Updates
 Table 85. Novartis lnternational AG Company Information
 Table 86. Novartis lnternational AG Description and Business Overview
 Table 87. Novartis lnternational AG Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis lnternational AG Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 89. Novartis lnternational AG Recent Developments/Updates
 Table 90. Bayer HealthCare Company Information
 Table 91. Bayer HealthCare Description and Business Overview
 Table 92. Bayer HealthCare Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Bayer HealthCare Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 94. Bayer HealthCare Recent Developments/Updates
 Table 95. United Therapeutics Corp. Company Information
 Table 96. United Therapeutics Corp. Description and Business Overview
 Table 97. United Therapeutics Corp. Primary Pulmonary Hypertension (PPH) Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. United Therapeutics Corp. Primary Pulmonary Hypertension (PPH) Treatment Product
 Table 99. United Therapeutics Corp. Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Primary Pulmonary Hypertension (PPH) Treatment Distributors List
 Table 103. Primary Pulmonary Hypertension (PPH) Treatment Customers List
 Table 104. Primary Pulmonary Hypertension (PPH) Treatment Market Trends
 Table 105. Primary Pulmonary Hypertension (PPH) Treatment Market Drivers
 Table 106. Primary Pulmonary Hypertension (PPH) Treatment Market Challenges
 Table 107. Primary Pulmonary Hypertension (PPH) Treatment Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Primary Pulmonary Hypertension (PPH) Treatment
 Figure 2. Global Primary Pulmonary Hypertension (PPH) Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Primary Pulmonary Hypertension (PPH) Treatment Market Share by Type: 2024 & 2031
 Figure 4. Prostacyclin & Prostacyclin Analogs Product Picture
 Figure 5. Endothelin Receptor Antagonists (ERAs) Product Picture
 Figure 6. Phosphodiesterase-5 (PDE-5)Inhibitors Product Picture
 Figure 7. Soluble Guanylate Cyclase (sGC) Stimulators Product Picture
 Figure 8. Global Primary Pulmonary Hypertension (PPH) Treatment Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Primary Pulmonary Hypertension (PPH) Treatment Market Share by Application: 2024 & 2031
 Figure 10. Early-stage Drug Candidates (Phase l & Phase ll)
 Figure 11. Late-stage Drug Candidates (Phase ll & Registration Phase)
 Figure 12. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Primary Pulmonary Hypertension (PPH) Treatment Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Primary Pulmonary Hypertension (PPH) Treatment Sales (2020-2031) & (K Units)
 Figure 15. Global Primary Pulmonary Hypertension (PPH) Treatment Average Price (US$/Unit) & (2020-2031)
 Figure 16. Primary Pulmonary Hypertension (PPH) Treatment Report Years Considered
 Figure 17. Primary Pulmonary Hypertension (PPH) Treatment Sales Share by Manufacturers in 2024
 Figure 18. Global Primary Pulmonary Hypertension (PPH) Treatment Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Primary Pulmonary Hypertension (PPH) Treatment Players: Market Share by Revenue in Primary Pulmonary Hypertension (PPH) Treatment in 2024
 Figure 20. Primary Pulmonary Hypertension (PPH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Primary Pulmonary Hypertension (PPH) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Country (2020-2031)
 Figure 23. North America Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 24. United States Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Country (2020-2031)
 Figure 27. Europe Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Region (2020-2031)
 Figure 35. China Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Primary Pulmonary Hypertension (PPH) Treatment Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Primary Pulmonary Hypertension (PPH) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Primary Pulmonary Hypertension (PPH) Treatment by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Primary Pulmonary Hypertension (PPH) Treatment by Type (2020-2031)
 Figure 54. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Primary Pulmonary Hypertension (PPH) Treatment by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Primary Pulmonary Hypertension (PPH) Treatment by Application (2020-2031)
 Figure 57. Global Primary Pulmonary Hypertension (PPH) Treatment Price (US$/Unit) by Application (2020-2031)
 Figure 58. Primary Pulmonary Hypertension (PPH) Treatment Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Point-of-care Troponin Testing Instrument Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22I19939
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Troponin Analyzer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38W19812
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Anticoagulant Medications Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-39V16824
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions